NICE Agrees With FDA in Pulling Avastin's Indication for Metastatic Breast Cancer

According to the final guidance issued by NICE this week, it appears that the drug sponsor did not submit data to the appraisal committee on biomarkers to stratify best responders to Avastin.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.